The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
all cause mortality was higher in clinical and lipid lowering studies and then the risk for neurocognitive events diabetes metis heart failure stroke um was higher in the Ali rukab studies in the 13 lipid lowering studies so there's 2.04 uh on the odds ratio for stroke and tia for the Ali rukab 1.23 for heart failure 1 .24 for diabetes 1.55 for neurocognitive events
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.